Young Shin Song

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9385165/publications.pdf

Version: 2024-02-01

31	1,318	17 h-index	32
papers	citations		g-index
32	32	32	1791
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Analyses of the Relation between BPPV and Thyroid Diseases: A Nested Case-Control Study. Diagnostics, 2021, 11, 329.	2.6	9
2	DEHP Down-Regulates Tshr Gene Expression in Rat Thyroid Tissues and FRTL-5 Rat Thyrocytes: A Potential Mechanism of Thyroid Disruption. Endocrinology and Metabolism, 2021, 36, 447-454.	3.0	12
3	Evaluation of the relationship between previous statin use and thyroid cancer using Korean National Health Insurance Service-Health Screening Cohort data. Scientific Reports, 2021, 11, 7912.	3.3	3
4	Increased expression of thyroid hormone receptor alpha and estrogen receptor alpha in breast cancer associated with thyroid cancer. European Journal of Surgical Oncology, 2021, 47, 1316-1323.	1.0	9
5	NTRK and RET fusion $\hat{a}\in\hat{a}$ directed therapy in pediatric thyroid cancer yields a tumor response and radioiodine uptake. Journal of Clinical Investigation, 2021, 131, .	8.2	62
6	Screening Leads to Overestimated Associations of Thyroid Dysfunction and Thyroiditis with Thyroid Cancer Risk. Cancers, 2021, 13, 5385.	3.7	2
7	Association between SSNHL and Thyroid Diseases. International Journal of Environmental Research and Public Health, 2020, 17, 8419.	2.6	6
8	Association between Ménière's disease and thyroid diseases: a nested case–control study. Scientific Reports, 2020, 10, 18224.	3.3	24
9	Genomic and Transcriptomic Characteristics According to Size of Papillary Thyroid Microcarcinoma. Cancers, 2020, 12, 1345.	3.7	12
10	Mechanisms of TERT Reactivation and Its Interaction with BRAFV600E. Endocrinology and Metabolism, 2020, 35, 515-525.	3.0	10
11	Recent Improvements in Genomic and Transcriptomic Understanding of Anaplastic and Poorly Differentiated Thyroid Cancers. Endocrinology and Metabolism, 2020, 35, 44.	3.0	21
12	CXCL16 positively correlated with M2-macrophage infiltration, enhanced angiogenesis, and poor prognosis in thyroid cancer. Scientific Reports, 2019, 9, 13288.	3.3	46
13	Integrative analysis of genomic and transcriptomic characteristics associated with progression of aggressive thyroid cancer. Nature Communications, 2019, 10, 2764.	12.8	166
14	Longitudinal Assessment of Quality of Life According to Treatment Options in Low-Risk Papillary Thyroid Microcarcinoma Patients: Active Surveillance or Immediate Surgery (Interim Analysis of) Tj ETQq0 0 0 rgE	3T (Osverlo	ck 1.6) Tf 50 21
15	A Novel Orally Active Inverse Agonist of Estrogen-related Receptor Gamma (ERRγ), DN200434, A Booster of NIS in Anaplastic Thyroid Cancer. Clinical Cancer Research, 2019, 25, 5069-5081.	7.0	24
16	Genomic Characterization of Differentiated Thyroid Carcinoma. Endocrinology and Metabolism, 2019, 34, 1 .	3.0	37
17	Aberrant Thyroid-Stimulating Hormone Receptor Signaling Increases VEGF-A and CXCL8 Secretion of Thyroid Cancer Cells, Contributing to Angiogenesis and Tumor Growth. Clinical Cancer Research, 2019, 25, 414-425.	7.0	28
18	Interaction of BRAF-induced ETS factors with mutant TERT promoter in papillary thyroid cancer. Endocrine-Related Cancer, 2019, 26, 629-641.	3.1	60

#	Article	IF	CITATIONS
19	Expression of Sodium-lodide Symporter Depending on Mutational Status and Lymphocytic Thyroiditis in Papillary Thyroid Carcinoma. International Journal of Thyroidology, 2018, 11, 152.	0.1	1
20	Star-Shaped Intense Uptake of 131I on Whole Body Scans Can Reflect Good Therapeutic Effects of Low-Dose Radioactive Iodine Treatment of 1.1 GBq. Endocrinology and Metabolism, 2018, 33, 228.	3.0	4
21	Effects of Maternal Iodine Status during Pregnancy and Lactation on Maternal Thyroid Function and Offspring Growth and Development: A Prospective Study Protocol for the Ideal Breast Milk Cohort. Endocrinology and Metabolism, 2018, 33, 395.	3.0	2
22	Comprehensive Transcriptomic and Genomic Profiling of Subtypes of Follicular Variant of Papillary Thyroid Carcinoma. Thyroid, 2018, 28, 1468-1478.	4.5	21
23	Study Protocol of Multicenter Prospective Cohort Study of Active Surveillance on Papillary Thyroid Microcarcinoma (MAeSTro). Endocrinology and Metabolism, 2018, 33, 278.	3.0	35
24	Loss-of-function of IFT88 determines metabolic phenotypes in thyroid cancer. Oncogene, 2018, 37, 4455-4474.	5.9	27
25	Effects of Coexistent <i>BRAF^{V600E}</i> Clinical Outcomes in Papillary Thyroid Cancer: A Meta-Analysis. Thyroid, 2017, 27, 651-660.	4.5	122
26	Changes in the clinicopathological characteristics and genetic alterations of follicular thyroid cancer. European Journal of Endocrinology, 2017, 177, 465-473.	3.7	26
27	Rare Manifestations of Anaplastic Thyroid Carcinoma: the Role of BRAF Mutation Analysis. Journal of Korean Medical Science, 2017, 32, 1721.	2.5	4
28	Graves' Patient with Thymic Expression of Thyrotropin Receptors and Dynamic Changes in Thymic Hyperplasia Proportional to Graves' Disease Activity. Yonsei Medical Journal, 2016, 57, 795.	2.2	10
29	Prognostic effects of <i>TERT</i> promoter mutations are enhanced by coexistence with <i>BRAF</i> or <i>RAS</i> mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients. Cancer, 2016, 122, 1370-1379.	4.1	147
30	Comprehensive Analysis of the Transcriptional and Mutational Landscape of Follicular and Papillary Thyroid Cancers. PLoS Genetics, 2016, 12, e1006239.	3 . 5	265
31	Mutation Profile of Well-Differentiated Thyroid Cancer in Asians. Endocrinology and Metabolism, 2015, 30, 252.	3.0	66